Article · 29 Dec 2025
Conference abstractPublished 27 Oct 2014
Risk assessment: A pragmatic approach to develop biosimilars
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Therapeutic proteins and antibodies are one of the most important and rapidly growing segments of the pharmaceutical industry. By 2016, yearly spending on brand biologics will reach $60 billion. But affordability of these life-saving drugs is a challenge specifically in the developing world. There is a pragmatic solution on the horizon for safe, affordable, biosimilar versions of these critical therapies. Biosimilars have been proved safe and efficacious in Europe for last seven years but in USA the guidelines from US FDA to develop biosimilars is still awaited. As we know the genesis of Biosimilars is providing cheap, affordable drugs for the masses, specifically in emerging markets where affordability of critical drugs is a major concern. In this presentation, the author will focus on how to design the development in a cost effective way keeping a close watch on Critical Quality Attributes (CQAs) of the drug. What and how much is required to establish the Biosimilarity of the drug is more important. There is a huge improvement in assays available during the development of innovator molecules and assays available now. It is now possible to accurately quantitate the chemical status of each residue in a protein molecule and measure minute structural variance using various orthogonal approaches. On top of that the relevance and extent of clinic trails for innovators and for biosimilars will be discussed too.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Harish Shandilya”

